Terns Pharmaceuticals, Inc.
TERN
株式のランク
#3579
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
株価
$52.95
最終同期: 2026-05-15
時価総額
$4.77B
変化（1日）
0.00%
変化（1年）
514.27%
国
US
取引 Terns Pharmaceuticals, Inc. (TERN)
カテゴリー
Healthcare
Terns Pharmaceuticals, Inc.（TERN）の株式分割履歴
Terns Pharmaceuticals, Inc.株（シンボル：TERN）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 20, 2026に行われました。
Oct 20, 2026より前に購入されたTERN株は、現在0TERN株に相当します。
最新の株式分割はOct 20, 2026に行われました。
Oct 20, 2026より前に購入されたTERN株は、現在0TERN株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 提供された日付のデータは十分ではありません。 | |||
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
